A Randomized, Controlled Phase III Study Investigating IMA901 Multipeptide Cancer Vaccine in Patients Receiving Sunitinib as First-line Therapy for Advanced/Metastatic Renal Cell Carcinoma

Trial Profile

A Randomized, Controlled Phase III Study Investigating IMA901 Multipeptide Cancer Vaccine in Patients Receiving Sunitinib as First-line Therapy for Advanced/Metastatic Renal Cell Carcinoma

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Jun 2017

At a glance

  • Drugs IMA 901 (Primary) ; Cyclophosphamide; Sunitinib
  • Indications Renal cancer; Renal cell carcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms IMPRINT
  • Sponsors immatics biotechnologies GmbH
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 03 Oct 2016 Efficacy and safety results (n=339) published in the Lancet Oncology.
    • 17 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top